Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

600 men to help uncover hidden causes of low testosterone

NCT ID NCT07476222

Knowledge-focused Sponsor: Andijan State Medical Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 26, 2026 · Updated 6 times

Summary

This study will examine 600 men aged 35-59 in Uzbekistan to find out which physical, lifestyle, and emotional factors are linked to low testosterone. Participants will have blood tests, physical measurements, and complete questionnaires. The goal is to create a model that helps doctors spot testosterone deficiency earlier.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help identify lifestyle and physical factors that predict low testosterone, leading to better prevention strategies for middle-aged men.
What could go wrong
This is an observational study, not a treatment trial. It cannot prove cause and effect, and results may not apply to men outside Uzbekistan.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 600 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will consist of middle-aged men aged 35-59 years residing in the Andijan region of Uzbekistan. Participants will be recruited through voluntary participation using community-based announcements, primary healthcare institutions, social media platforms and workplace outreach. Eligible participants will undergo a comprehensive assessment including standardized anthropometric measurements, functional performance tests, validated questionnaires assessing lifestyle-related factors and symptoms suggestive of testosterone deficiency, and laboratory determination of serum total testosterone concentrations.

Ages

35 to 59 years

Sex

Male participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Men aged 35-59 years * Permanent residence in the Andijan region of Uzbekistan * Ability and willingness to provide written informed consent * Willingness to undergo clinical, anthropometric, functional and laboratory assessments Exclusion Criteria: * Previously diagnosed hypogonadism requiring testosterone replacement therapy * Current use of testosterone preparations or other medications known to substantially affect androgen status * Severe cardiovascular, hepatic or renal disease in the stage of decompensation * Clinically significant urological pathology * Severe psychiatric illness or cognitive impairment limiting study participation * Acute infectious or inflammatory conditions at the time of assessment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Androgen deficiency are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

eunuchism hypogonadism hypogonadism, male insomnia Motor Activity Sarcopenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Androgen deficiency Late-onset hypogonadism Male hypogonadism Testosterone deficiency

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Andijan State Medical Institute

    RECRUITING

    Andijan, 170127, Uzbekistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.